enGene Therapeutics Inc. (ENGN) › Cash & EquivalentsenGene Therapeutics Inc. (ENGN) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2022-10-31: $20.43M2023-10-31: $81.52M2024-10-31: $173.00M2025-10-31: $50.15M$50.15M2022-10-31Cash & Equivalents (USD)2025-10-31Period endedCash & EquivalentsChange YoYSource filing2025-10-31$50.15M-71.0%2025-12-22Balance as of period end2024-10-31$173.00M+112.2%2025-12-22Balance as of period end2023-10-31$81.52M+298.9%2024-12-19Balance as of period end2022-10-31$20.43M—2024-01-29Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)